TOKYO, Apr 15 (Pulse News Wire) – StemRIM Inc. (4599.T) announced today that patient enrollment for its Phase I/II physician-led trial of regenerative medicine drug LeDaseumtid (HMGB1 peptide) targeting ischemic cardiomyopathy patients has been completed.
The trial, conducted primarily at Osaka University Hospital and involving five facilities, enrolled 14 patients who underwent coronary artery bypass surgery. Patients received either LeDaseumtid or placebo for five days, with safety and tolerability evaluations as primary endpoints. Secondary efficacy assessments will be based on various cardiac function tests conducted 52 weeks post-treatment.
Initially planned to enroll 20 patients (10 in each treatment group), the trial concluded with 14 patients due to sufficient data for evaluating safety and tolerability. Detailed information on the clinical study can be found on the Japan Registry of Clinical Trials (jRCT) database. As of now, there is no expected impact on the company's fiscal year ending July 2026 results from this trial.
🟢 Confidence: High AI-translated content.